IMV Inc.completes private placement for the development of drug candidates and clinical trials

On May 7, 2020, IMV Inc. completed a non-brokered private placement of 8,770,005 units at C$2.86 per unit.

IMV Inc. will use the net proceeds from the private placement to support the development of its lead immunotherapy and vaccine candidates, and fund clinical trials and research. Along with its ongoing development of cancer treatments and preventative medicines, IMV Inc. is developing a COVID-19 vaccine candidate.

IMV Inc. is a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases.

McCarthy Tetrault advised IMV Inc. with a team co-led by Philippe Leclerc that included Myreille Gilbert, Annie Poirier-Simard and David Martin.